PhD, Director of Biotechnology, and Innovation
Fernando is the recipient of the 2015 Scripps CHAVI-ID Young Investigator Award for his exceptional contributions to the development of an anti-HIV-1 vaccine.
Fernando received his bachelor’s degree in Microbiology from the Catholic University in Porto, Portugal. His research journey began in 2004 when he was granted an international PhD fellowship at the University of Barcelona, Spain. After completing his doctoral studies in Structural Biology and Biochemistry, he moved to the Institute of Cancer Research in London, UK, to take on his first postdoctoral research fellowship. Here, his focus was on proteins involved in DNA Repair, exploring their potential as targets for oncology, including a drug discovery project in collaboration with AstraZeneca.
In 2012, he embarked on his second postdoctoral experience at Professor Ian Wilson’s lab at The Scripps Research Institute in San Diego, California, where he honed his expertise in structure-guided protein design applied to an HIV-1 vaccine.
In 2016, Fernando embarked on a new chapter at Amgen, where he established and led a pioneering Protein Engineering team at the interface of computational protein design and Protein Sciences. Many of his breakthroughs contributed to a better understanding of the structure/developability relationship for Multispecific Antibodies, delivering an industry-leading workflow for this new class of biologics. Additional contributions included the design of three bispecific molecules that reached phase I and several peer-reviewed articles.
In 2021, Fernando joined Gilead as Director of Protein Therapeutics. Here, he was entrusted with building the Next Gen Biologics Engineering (NGBE) team and the required infrastructure to enable Biologics.
Throughout his academic and private research career, Fernando has co-authored approximately 35 peer-reviewed publications and secured more than 20 patents.